A Multicenter Randomized Controlled Trial Comparing the Quality of Life Between Laparoscopy-assisted Distal Gastrectomy and Totally Laparoscopic Distal Gastrectomy for Gastric cancer_KLASS 07 (CKLASS01)(Korea-China Collaborated Study)

The present randomized study is designed to compare the quality of life between the patients undergoing laparoscopy-assisted and totally laparoscopic distal gastrectomy for gastric cancer, and therefore to evaluate the superiority of totally laparoscopic distal gastrectomy to laparoscopy-assisted distal gastrectomy.

Start Date01 Mar 2018

Sponsor / Collaborator

Korea University Anam Hospital

[+1]

ChiCTR-TRC-11001442

/ CompletedPhase 4IIT

The effect of dexmedetomidine on intravenous analgesia after caesarean section

Start Date01 Mar 2010

Sponsor / Collaborator

Shanghai Medical College of Fudan University

100 Clinical Results associated with Shanghai Medical College of Fudan University

0 Patents (Medical) associated with Shanghai Medical College of Fudan University

5,744

Literatures (Medical) associated with Shanghai Medical College of Fudan University

01 May 2025·New Biotechnology

Advances in the development of microarray patches in biomedicine

Article

Author: Jamaledin, Rezvan ; Moon, Tae Seok ; Wang, Xiangdong ; Mofidfar, Mohammad ; Makvandi, Pooyan

Microarray patches (MAPs) have been employed to deliver therapeutic payloads and for detection purposes. Research has been conducted to develop novel designs in material chemistry and the architecture of microarray, which have opened up the possibility for broader applications of MAPs. However, MAPs have yet to be clinically implemented fully. Addressing the current challenges and maximizing opportunities will pave the way to translate the relevant technologies from bench to bedside.

01 Jan 2025·Molecular & Cellular Proteomics

Nuclear Factor I Family Members are Key Transcription Factors Regulating Gene Expression

Article

Author: Göös, Helka ; Varjosalo, Markku ; Malaymar Pinar, Dicle ; Tan, Zenglai ; Wang, Zixian ; Kumpula, Esa-Pekka ; Chowdhury, Iftekhar ; Wei, Gong-Hong ; Zhang, Qin ; Kumbasar, Asli ; Keskitalo, Salla ; Salokas, Kari

The Nuclear Factor I (NFI) family of transcription factors (TFs) plays key roles in cellular differentiation, proliferation, and homeostasis. As such, NFI family members engage in a large number of interactions with other proteins and chromatin. However, despite their well-established significance, the NFIs' interactomes, their dynamics, and their functions have not been comprehensively examined. Here, we employed complementary omics-level techniques, i.e. interactomics (affinity purification mass spectrometry (AP-MS) and proximity-dependent biotinylation (BioID)), and chromatin immunoprecipitation sequencing (ChIP-Seq), to obtain a comprehensive view of the NFI proteins and their interactions in different cell lines. Our analyses included all four NFI family members, and a less-studied short isoform of NFIB (NFIB4), which lacks the DNA binding domain. We observed that, despite exhibiting redundancy, each family member had unique high-confidence interactors and target genes, suggesting distinct roles within the transcriptional regulatory networks. The study revealed that NFIs interact with other TFs to co-regulate a broad range of regulatory networks and cellular processes. Notably, time-dependent proximity-labeling unveiled a highly dynamic nature of NFI protein-protein interaction networks and hinted at the temporal modulation of NFI interactions. Furthermore, gene ontology (GO) enrichment analysis of NFI interactome and targetome revealed the involvement of NFIs in transcriptional regulation, chromatin organization, cellular signaling pathways, and pathways related to cancer. Additionally, we observed that NFIB4 engages with proteins associated with mRNA regulation, which suggests that NFIs have roles beyond traditional DNA binding and transcriptional modulation. We propose that NFIs may function as potential pioneering TFs, given their role in regulating the DNA binding ability of other TFs and their interactions with key chromatin remodeling complexes, thereby influencing a wide range of cellular processes. These insights into NFI protein-protein interactions and their dynamic, context-dependent nature provide a deeper understanding of gene regulation mechanisms and hint at the role of NFIs as master regulators.

01 Jan 2025·Cell Reports

Transketolase attenuates the chemotherapy sensitivity of glioma cells by modulating R-loop formation

Article

Author: Wang, Pu ; Fu, Minjie ; Wu, Yonghe ; Zhang, Jinsen ; Peng, Tianping ; Hua, Wei ; Mao, Ying ; Feng, Yuan ; Ye, Dan ; Gao, Chao ; Zhang, Mengli ; Chu, Youjun ; Xu, Hao ; Zhang, Licheng ; Zhang, Huaichao

Glioblastoma (GBM) is a highly lethal malignant brain tumor with poor survival rates, and chemoresistance poses a significant challenge to the treatment of patients with GBM. Here, we show that transketolase (TKT), a metabolic enzyme in the pentose phosphate pathway (PPP), attenuates the chemotherapy sensitivity of glioma cells in a manner independent of catalytic activity. Mechanistically, chemotherapeutic drugs can facilitate the translocation of TKT protein from the cytosol into the nucleus, where TKT physically interacts with XRN2 to regulate the resolution and removal of R-loops. Depletion of TKT leads to increased R-loop accumulation and genome instability, increasing the susceptibility of glioma cells to chemotherapy. In conclusion, our study reveals a non-metabolic function of TKT in regulating R-loop dynamics, genome instability, and chemotherapy sensitivity in gliomas.

News (Medical) associated with Shanghai Medical College of Fudan University

28 Oct 2024

·www.prnewswire.com

MitrAssist Lifesciences Announces Promising Initial Clinical Results for SIKELIA™ Polymeric Heart Valve at TCT Conference 2024

WASHINGTON, Oct. 28, 2024 /PRNewswire/ -- MitrAssist Lifesciences, a leader in innovative cardiovascular medical devices, today unveiled the initial clinical results of its groundbreaking new product, SIKELIA™, during the 2024 Transcatheter Cardiovascular Therapeutics (TCT) Conference held in Washington, D.C. The early findings demonstrate promising potential in improving outcomes for patients suffering from severe symptomatic aortic stenosis. SIKELIA transthoracic heart valve (THV) is designed for transcatheter aortic valve implantation (TAVI) procedure. It features a unique polymer leaflet design which allows enhanced durability and reduced thrombogenicity and calcification while lowering production costs. SIKELIA THV is also fully retrievable at 100% frame expansion allowing reposition in case of misplacement. The clinical trial results, involving 12 patients from 4 centers, with a maximum follow up of 27 months, revealed favorable safety and performance 1-year outcomes. A significant improvement in hemodynamic performance was demonstrated by reduced mean pressure gradient and increased effective orifice area. The functional status as assessed by NYHA class, 6-minute walk test and KCCQ score was improved significantly in all measures. In addition, at 1 year follow-up, normal leaflet mobility without hypoattenuated leaflet thickening (HALT) or calcification was confirmed in all patients. "The initial clinical results of SIKELIA™ mark a significant milestone in our mission to transform patient care," said Peggy Wang, CEO of MitrAssist. "We are excited about the potential SIKELIA has to improve outcomes for patients suffering from severe aortic stenosis. SIKELIA capabilities and these initial results provide a foundation for the next phases of clinical testing, and we look forward to continuing our work to bring this innovation to physicians and patients around the world." The presentation at the TCT Conference attracted the attention of top physicians, industry leaders and medical professionals eager to explore more about the product. Dr. Xiaochun Zhang from Zhongshan Hospital and the Shanghai Medical College of Fudan University presented the initial results of this first-in-human, prospective, single-arm, multicenter study, on behalf of the study investigators. In addition to Zhongshan Hospital, the participating centers included Fuwai Yunnan Hospital, Chinese Academy of Medical Sciences, Xiamen Cardiovascular Hospital Xiamen University and Zibo Central Hospital. "The initial outcomes we are seeing from SIKELIA™ could represent a real breakthrough in the TAVR field," said Prof. Junbo Ge from Zhongshan Hospital, principal investigator of the clinical trial. "The potential for improving patients' outcomes is immense, and we are eager to continue gathering data and enhancing the application of this technology. These results are just the beginning, and they pave the way for more comprehensive studies in the near future." For further information, please visit MITRASSIST LIFESCIENCES LIMITED is a leading global company for innovative cardiovascular medical devices, focusing on providing advanced diagnostic and therapeutic solutions for cardiovascular patients. The company product line covers a wide range of applications in the cardiovascular field from structural heart disease to heart failure. MitrAssist is dedicated and committed to innovation and improving patient care. Logo: SOURCE MitrAssist Lifesciences WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultAHA

100 Deals associated with Shanghai Medical College of Fudan University

100 Translational Medicine associated with Shanghai Medical College of Fudan University

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 03 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Current Projects

Drug(Targets)	Indications	Global Highest Phase

CAR-GPC3 T cells ( GPC3 )	Hepatocellular Carcinoma More	Preclinical
ZSH-2208 ( RARγ x TNFAIP3 )	Esophageal Squamous Cell Carcinoma More	Preclinical
ONO-4127 ( PGD2 receptor )	Sleep Initiation and Maintenance Disorders More	Preclinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis